

HRN: ID Card:

OncoPROSTATE Dx - Order Form

Biochemistry

Serum Tumor Markers: PSA Total PSA Free p2PSA
 hK2
Urine Tumor Markers: Progensa PCA3 T2:ERG

Anamnesis

Personal Data

Race: African Hispanic/Latino Other
 Unknown

Age (years):

Comorbidities

Benign Prostatic Hyperplasia: Yes No Unknown
Prostatic Infarction: Yes No Unknown
Prostatitis: Yes No Unknown
Urinary Tract Infection: Yes No Unknown

Order Information

Ordered by: Signature:
Order Date:

Disclaimer

According to Annex VII of Medical Device Directive 93/42/EEC, Class I, Rule 12, OncoPROSTATE Dx is a non-invasive blood test useful to suggest a possible diagnosis in men with suspected malignancy in the prostate, reduce inappropriate diagnostic tests, days of hospitalization, as well as morbidity. It is specially designed for men with previous image findings suspicious of Prostate Cancer that should be biopsied to verify malignancy, as well as men older than 50 years with PSA higher than 4 ng/mL.

OncoPROSTATE Dx is based in a panel consisting of 4 serum Tumor Markers (PSA, fPSA, p2PSA and hK2), 2 urine Tumor Markers (Post-DRE PCA3 and Post-DRE T2:ERG), as well as clinical data to obtain the best performance (Sensitivity of 81.7% and Specificity of 98.2%), by reducing the number of false positives generated by benign comorbidities and other well-known causes.

